different kinds of glp-1 The Agonists and Obesity: How Diabetes Drugs are Changing Non-Diabetic Lives — tl;dr pharmacy Designing GLP-1 delivery: structural perspectives

Without that evidence, the safer approach is to pause peptide use through pregnancy and breastfeeding, then revisit once that window closes

Novartis is investing in expanding Pluvicto's label into pre-taxane prostate cancer (SPLASH trial submission pending), and developing next-generation RLT approaches targeting breast cancer and other tumour types positioning it to maintain leadership in the highest-growth oncology peptide segment

The review delves into the intricacies of different modification approaches, including N and C-terminal modifications, Fatty acid Side chain Modifications, and Large Molecule Conjugation Modifications, highlighting their rationale and resulting improvements in half-life, stability, receptor binding, and bioactivity

Hashioka, Sadayuki, Youn-Hee Han, Shunsuke Fujii, Takahiro Kato, Akira Monji, Hideo Utsumi, Makoto Sawada, Hiroshi Nakanishi, and Shigenobu Kanba